A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential ...

A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

A team of researchers at the University of Minnesota recently completed a human trial for a novel gene-editing treatment, ...

Shares of Kura Oncology KURA have rallied 15.5% in the past week against the industry’s decline of 0.1%. Earlier this week, ...

We have previously reported an association between increased sedation use and lower rates of post endoscopy upper GI cancer. We have analysed sedation practices for diagnostic upper GI endoscopy in ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

A French pharmaceutical giant is acquiring a Cambridge, Mass. biotech and its rare immunology disease treatment which is ...

Sanofi will gain Blueprint's Ayvakit, a treatment for systemic mastocytosis and gastrointestinal stromal tumors, among other therapies in its pipeline.

SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.

Preclinical data has showing compelling findings for HT-KIT among patients with rare and aggressive KIT-driven cancers, ...

Scientists have discovered a range of 'biomarkers' that could help to improve detection and treatment of gastrointestinal ...